Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Will Use REMS Program Data To Show Actemra Is Safe For First-Line RA

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss pharma's Genentech unit announced tocilizumab approval for failed TNF patients Jan. 8, saying it is committed to seek earlier uses with post-marketing data, including data from pharmacovigilance and risk plans as well as clinical studies.

You may also be interested in...



JAK Inhibitors Could Face Scrutiny Over Cholesterol Effects

As positive efficacy data rolls in for the janus kinase inhibitors in rheumatoid arthritis, like Pfizer’s Phase III tasocitinib, elevated lipid levels are emerging as an issue worth keeping an eye on.

JAK Inhibitors Could Face Scrutiny Over Cholesterol Effects

As positive efficacy data rolls in for the janus kinase inhibitors in rheumatoid arthritis, like Pfizer’s Phase III tasocitinib, elevated lipid levels are emerging as an issue worth keeping an eye on.

Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?

Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel